To conduct a systematic review and meta-analysis of the role of SBRTdrug combination in patients affected by mRCC and associated oncologic outcomes and toxicity profiles.
We performed a critical review of the Pubmed, Medline, and Embase databases from January 1, 2000 through April 30, 2020 according to the Preferred Reporting Items and Meta-Analyses statement. To assess the overall quality of the literature reviewed, we used a modified Delphi tool.
A total of 6 studies were included, corresponding to a cohort of 216 patients. Tyrosine Kinases Inhibitors were the most widely used drugs in combination with SBRT, being administered in 93% patients. No study reported an increase of radiation-induced toxicity.
SBRT resulted to be safe, without increase in terms of drugs-related adverse events in this setting. Moreover, this approach showed promising clinical outcomes in terms of LC and OS.
Critical reviews in oncology/hematology. 2021 Feb 02 [Epub ahead of print]
Gianluca Ingrosso, Carlotta Becherini, Giulio Francolini, Andrea Lancia, Emanuele Alì, Saverio Caini, Maria Ausilia Teriaca, Alessandro Marchionni, Andrea Riccardo Filippi, Lorenzo Livi, Giuseppe Sanguineti, Cynthia Aristei, Beatrice Detti
Radiation Oncology Section, Department of Surgical and Biomedical Science, University of Perugia, Italy., Radiation Oncology, A.O.U. Careggi, University of Florence, Florence, Italy., Radiation Oncology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy., Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Networking, Florence, Italy., Dept. of Radiation Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Radiation Oncology, A.O.U. Careggi, University of Florence, Florence, Italy. Electronic address: .